高级检索
当前位置: 首页 > 详情页

ERBB2-Mutated Metastatic Non-Small Cell Lung Cancer: Response and Resistance to Targeted Therapies

文献详情

资源类型:
机构: [1]Stanford Hosp & Clin, Div Hematol & Oncol, Stanford, CA USA; [2]Stanford Univ, Stanford Canc Inst, Stanford, CA 94305 USA; [3]Sun Yat Sen Univ, Dept Med Oncol, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China,Canc Ctr, Guangzhou, Guangdong, Peoples R China; [4]Stanford Univ, Div Oncol, Dept Med, Sch Med, Stanford, CA 94305 USA; [5]Palo Alto Vet Adm Hlth Care Syst, Palo Alto, CA USA; [6]Stanford Univ, Dept Radiat Oncol, Stanford, CA 94305 USA
出处:
ISSN:

关键词: ERBB2 HER2 Targeted therapy Afatinib Trastuzumab

摘要:
Introduction: Erb-b2 receptor tyrosine kinase 2 gene (ERBB2) (also called HER2) has long been recognized as an oncogenic driver in some breast and gastroesophageal cancers in which amplification of this gene confers sensitivity to treatment with Erb-b2 receptor tyrosine kinase 2 (ERBB2)-directed agents. More recently, somatic mutations in ERBB2 have been reported in 1% to 2% of patients with lung adenocarcinoma. Previous case series have suggested clinical tumor responses using antiERBB2 small molecules and antibody therapies. Methods: Here we report the outcomes of nine patients with metastatic lung adenocarcinoma with ERBB2 mutations being treated with ERBB2-targeted therapies. Results: Four of the nine patients had response to targeted therapies, with durations of response ranging from 3 to 10 months. We identified a de novo phosphatidylinositol-4,5bisphosphate 3-kinase catalytic subunit alpha gene (PIK3CA) mutation and ERBB2 copy number gain as potential resistance mechanisms. Conclusions: We showed patients with ERBB2-mutated lung adenocarcinoma can respond to targeted therapies, and we identified potential resistance mechanisms upon progression to targeted therapies. (C) 2017 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2017]版:
大类 | 2 区 医学
小类 | 2 区 肿瘤学 2 区 呼吸系统
最新[2023]版:
大类 | 1 区 医学
小类 | 1 区 肿瘤学 1 区 呼吸系统
第一作者:
第一作者机构: [1]Stanford Hosp & Clin, Div Hematol & Oncol, Stanford, CA USA;
通讯作者:
通讯机构: [4]Stanford Univ, Div Oncol, Dept Med, Sch Med, Stanford, CA 94305 USA;
推荐引用方式(GB/T 7714):
APA:
MLA:

相关文献

[1]Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): An open-label, randomised, phase 3 trial [2]Differences in axillary response and treatment implications in HER2 positive node positive breast cancer during neoadjuvant HER2 targeted dual therapy [3]Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer [4]Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer [5]HER2-targeted therapies in cancer: a systematic review [6]Unraveling the future: Innovative design strategies and emerging challenges in HER2-targeted tyrosine kinase inhibitors for cancer therapy [7]Detection of ERBB2 (HER2) amplification by next-generation sequencing (NGS) in patients (pts) with gastrointestinal (GI) cancer [8]CD55 and CD59 expression protects HER2-overexpressing breast cancer cells from trastuzumab-induced complement-dependent cytotoxicity. [9]A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH) [10]A Study to Learn More About How Well BAY 2927088 Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Human Epidermal Growth Factor Receptor 2 (HER2)

资源点击量:46425 今日访问量:0 总访问量:3323 更新日期:2024-11-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号